TipRanks
Go Ultimate55% OFF

Paul Geyer Insider Profile

109 Followers

Paul Geyer, Director at Eupraxia Pharmaceuticals, holds 374.07K shares in Eupraxia Pharmaceuticals (Ticker: TSE:EPRX), holds 2.64M shares in TIMIA Capital (Ticker: TSE:MONT), holds 351.46K shares in Neovasc (Ticker: NVCN). Most recently, Paul Geyer Sold ― shares of Eupraxia Pharmaceuticals on Mar 19, 2026 for an estimated value of C$162.00K.

Paul Geyer's Trading History

EPRX
Eupraxia Pharmaceuticals
Mar 19, 2026DirectorInformative Sell162.00KC$3.56M
MONT
TIMIA Capital
Mar 08, 2024DirectorInformative Buy21.25KC$26.39K
NVCN
Neovasc
Nov 24, 2022―Informative Buy19.50K$10.55M

You May Also Like

Paul Geyer insider profile FAQ

What is the percentage of profitable transactions made by Paul Geyer?
The percentage of profitable transactions made by Paul Geyer is 54%.
What is the average return per transaction made by Paul Geyer?
The average return per transaction made by Paul Geyer is 27.90%.
What stocks does Paul Geyer hold?
Paul Geyer holds: TSE:EPRX, NVCN, TSE:MONT stocks.
What was Paul Geyer’s latest transaction?
Paul Geyer’s latest transaction was an Informative Sell of C$162.00K.
What was Paul Geyer's most profitable transaction?
Paul Geyer’s most profitable transaction was an Informative Buy of TSE:EPRX stock on April 25, 2022. The return on the trade was 306.60%.
What is Paul Geyer's role in Eupraxia Pharmaceuticals?
Paul Geyer's role in Eupraxia Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.